{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:19:00Z","timestamp":1787321940555,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cpcardiol.2026.103409","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:16:34Z","timestamp":1785770194000},"page":"103409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and tolerability of sodium\u2013glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy: A systematic review and stratified meta-analysis"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8383-7542","authenticated-orcid":false,"given":"Roberta","family":"Magnano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3815-457X","authenticated-orcid":false,"given":"Silvio","family":"Saraullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Zuardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"D\u2019Alleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Di","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0195-6511","authenticated-orcid":false,"given":"Claudio","family":"Scollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Genovesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Guarracini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Forlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiusto","family":"Vitulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Renda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo Di","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.cpcardiol.2026.103409_bib0001","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.cpcardiol.2026.103409_bib0002","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103409_bib0003","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103409_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/eurheartj\/ehaf710","article-title":"Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC heart failure association","volume":"47","author":"Garcia-Pavia","year":"2026","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103409_bib0005","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","article-title":"Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine","volume":"46","author":"Gonzalez-Lopez","year":"2025","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103409_bib0006","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin Amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.cpcardiol.2026.103409_bib0007","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.cpcardiol.2026.103409_bib0008","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of Tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103409_bib0009","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"31","key":"10.1016\/j.cpcardiol.2026.103409_bib0010","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103409_bib0011","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.cpcardiol.2026.103409_bib0012","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103409_bib0013","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103409_bib0014","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103409_bib0015","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/ejhf.2584","article-title":"Side effects and treatment initiation barriers of sodium\u2013glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis","volume":"24","author":"Vukadinovi\u0107","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"10.1016\/j.cpcardiol.2026.103409_bib0016","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103409_bib0017","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103409_bib0018","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103409_bib0019","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.cpcardiol.2026.103409_bib0020","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103409_bib0021","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"24","key":"10.1016\/j.cpcardiol.2026.103409_bib0022","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 Inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.cpcardiol.2026.103409_bib0023","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.3390\/jcm13195966","article-title":"Impact of SGLT2-inhibitor therapy on survival in patients with transthyretin amyloid cardiomyopathy: analysis of a prospective registry study","volume":"13","author":"Schwegel","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.cpcardiol.2026.103409_bib0024","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.amjcard.2025.01.012","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in transthyretin amyloid cardiomyopathy","volume":"243","author":"Byer","year":"2025","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103409_bib0025","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jchf.2025.01.025","article-title":"Sodium-glucose cotransporter 2 inhibitors in tafamidis-treated transthyretin amyloid cardiomyopathy","volume":"13","author":"Chi","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103409_bib0026","article-title":"Sodium-glucose cotransporter 2 inhibitors for wild-type transthyretin amyloidosis: insights from a global database","volume":"60","author":"Zathar","year":"2025","journal-title":"Am Heart J Plus Cardiol Res Pr"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103409_bib0027","doi-asserted-by":"crossref","first-page":"160","DOI":"10.36628\/ijhf.2026.0010","article-title":"Sodium-glucose cotransporter-2 inhibitors therapy in transthyretin amyloid cardiomyopathy: a propensity-matched cohort study","volume":"8","author":"Pinheiro","year":"2026","journal-title":"Int J Heart Fail"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103409_bib0028","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/jcm13010283","article-title":"Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis\u2014a clinical feasibility study","volume":"13","author":"Steinhardt","year":"2024","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103409_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101405","article-title":"Sodium-glucose cotransporter 2 inhibitor use and outcomes in transthyretin amyloid cardiomyopathy","volume":"3","author":"Jaiswal","year":"2024","journal-title":"JACC Adv"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103409_bib0030","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium\u2013Glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103409_bib0031","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.recesp.2023.10.007","article-title":"Uso de iSGLT2 en pacientes con amiloidosis cardiaca por transtirretina: prevalencia y seguridad en una cohorte prospectiva en Espa\u00f1a","volume":"77","author":"Gonz\u00e1lez-Montes","year":"2024","journal-title":"Rev Esp Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103409_bib0032","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 Inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to Dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103409_bib0033","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.hrthm.2024.09.002","article-title":"Impact of SGLT2 inhibitors on the outcomes of patients with cardiac arrhythmias and transthyretin cardiac amyloidosis","volume":"22","author":"Sivamurugan","year":"2025","journal-title":"Heart Rhythm"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103409_bib0034","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s11739-022-02944-8","article-title":"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series","volume":"17","author":"Zampieri","year":"2022","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.cpcardiol.2026.103409_bib0035","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.72725","article-title":"The role of sodium-glucose cotransporter-2 inhibitors in adults with transthyretin cardiac amyloidosis: a single-center retrospective cohort study","author":"Pillai","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103409_bib0036","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jjcc.2025.10.004","article-title":"Combination therapy with SGLT2-inhibitors and tafamidis in transthyretin cardiomyopathy","volume":"87","author":"Chung","year":"2026","journal-title":"J Cardiol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103409_bib0037","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.amjmed.2025.02.010","article-title":"Sodium-glucose cotransporter 2 inhibitors in patients with amyloidosis with or without heart failure","volume":"138","author":"Augusto","year":"2025","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103409_bib0038","first-page":"994","article-title":"Effect of sodium-glucose cotransporter type 2 inhibitors on the course of heart failure in patients with amyloid cardiomyopathy: results of a pilot single-center randomized trial","volume":"97","author":"Shoshina","year":"2026","journal-title":"Ter Arkh"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103409_bib0039","doi-asserted-by":"crossref","DOI":"10.36660\/abc.20250439i","article-title":"Sodium-glucose cotransporter 2 inhibitors in patients with heart failure and transthyretin or light chain amyloidosis: a real-world analysis","volume":"123","author":"Nunes","year":"2026","journal-title":"Arq Bras Cardiol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103409_bib0040","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14392","article-title":"Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: systematic review and meta-analysis","volume":"55","author":"Karakasis","year":"2025","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103409_bib0041","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/ehjcvp\/pvaf033","article-title":"Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies","volume":"11","author":"Laborante","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103409_bib0042","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","article-title":"Kidney outcomes in transthyretin amyloid cardiomyopathy","volume":"10","author":"Ioannou","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103409_bib0043","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jchf.2024.03.012","article-title":"Myocardial mitochondrial function is impaired in cardiac light-chain amyloidosis compared to transthyretin amyloidosis","volume":"12","author":"Vo\u00df","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103409_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2025.103081","article-title":"Early prescription of SGLT2i for acute patient care: from current evidence to future directions","volume":"50","author":"Ricci","year":"2025","journal-title":"Curr Probl Cardiol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103409_bib0045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103409_bib0046","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"37","key":"10.1016\/j.cpcardiol.2026.103409_bib0047","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1093\/eurheartj\/ehad389","article-title":"Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction","volume":"44","author":"Pandey","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103409_bib0048","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12933-023-01822-7","article-title":"Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review","volume":"22","author":"Hoehlschen","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103409_bib0049","article-title":"Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction","volume":"14","author":"Xia","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103409_bib0050","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40842-025-00252-6","article-title":"SGLT2 inhibitors in cardiac amyloidosis: mechanistic insights and clinical perspectives\u2014a narrative review","volume":"11","author":"\u00d6zlek","year":"2025","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103409_bib0051","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamacardio.2023.0077","article-title":"Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction","volume":"8","author":"Cohen","year":"2023","journal-title":"JAMA Cardiol"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626001519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626001519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:16:25Z","timestamp":1787318185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280626001519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0146280626001519"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103409","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of sodium\u2013glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy: A systematic review and stratified meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103409"}}